Through the 90-day period concluding February 07, 2026, Travere Therapeutics's top three insider stakeholders include Chief Executive Officer Eric M Dube (432.89K shares), Director Steve Aselage (166.42K shares), Chief Commercial Officer Peter Heerma (131.82K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Eric M Dube | Chief Executive Officer | 432,886 | 03 Feb, 2026 |
| Steve Aselage | 166,419 | 12 May, 2022 | |
| Peter Heerma | Chief Commercial Officer | 131,823 | 03 Feb, 2026 |
| Christopher R. Cline | Chief Financial Officer | 111,226 | 05 Feb, 2026 |
| William E. Rote | Chief Research Officer | 109,087 | 03 Feb, 2026 |
| Jula Inrig | Chief Medical Officer | 105,706 | 05 Feb, 2026 |
| Elizabeth E Reed | Chief Legal Officer And Gc | 105,211 | 05 Feb, 2026 |
| Jeffrey A Meckler | 87,500 | 16 May, 2025 | |
| Gary A Lyons | 57,500 | 16 May, 2025 | |
| Timothy Coughlin | 55,500 | 04 Nov, 2025 | |
| Sandra Calvin | Svp And Chief Accounting Officer | 49,080 | 03 Feb, 2026 |
| Noah L. Rosenberg | Chief Medical Officer | 47,614 | 17 Aug, 2021 |
| Roy D. Baynes | 37,500 | 16 May, 2025 | |
| Laura Clague | Chief Financial Officer | 35,655 | 12 May, 2022 |
| John A Orwin | 35,375 | 16 May, 2025 | |
| Ron Squarer | 35,375 | 16 May, 2025 | |
| Sandra Poole | 30,000 | 16 May, 2025 | |
| Suzanne Louise Bruhn | 28,750 | 16 May, 2025 | |
| Brinkley Ruth Williams | 25,750 | 16 May, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 04 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 2,485 | $32.07 | 105,720 | D | S |
| 04 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 509 | $32.74 | 105,211 | D | S |
| 04 Feb, 2026 | Jula Inrig | Common Stock | D | 1,547 | $32.11 | 105,938 | D | S |
| 04 Feb, 2026 | Jula Inrig | Common Stock | D | 232 | $32.85 | 105,706 | D | S |
| 04 Feb, 2026 | Christopher R. Cline | Common Stock | D | 1,635 | $32.14 | 111,336 | D | S |
| 04 Feb, 2026 | Christopher R. Cline | Common Stock | D | 110 | $32.90 | 111,226 | D | S |
| 03 Feb, 2026 | Elizabeth E Reed | Common Stock | D | 7,175 | $32.12 | 108,205 | D | S |
| 03 Feb, 2026 | William E. Rote | Common Stock | D | 12,446 | $32.87 | 109,087 | D | S |
| 03 Feb, 2026 | Eric M Dube | Common Stock | D | 33,635 | $32.70 | 432,886 | D | S |
| 03 Feb, 2026 | Eric M Dube | Common Stock | D | 66,452 | $32.06 | 466,521 | D | S |
| 03 Feb, 2026 | Peter Heerma | Common Stock | D | 7,310 | $32.12 | 131,823 | D | S |
| 03 Feb, 2026 | Sandra Calvin | Common Stock | D | 4,333 | $32.12 | 49,080 | D | S |
| 03 Feb, 2026 | Jula Inrig | Common Stock | D | 6,956 | $32.12 | 107,485 | D | S |
| 03 Feb, 2026 | Christopher R. Cline | Common Stock | D | 7,242 | $32.12 | 112,971 | D | S |
| 31 Jan, 2026 | Elizabeth E Reed | Common Stock | A | 25,110 | $0.00 | 115,380 | D | A |
| 31 Jan, 2026 | William E. Rote | Common Stock | A | 20,090 | $0.00 | 121,533 | D | A |
| 31 Jan, 2026 | Eric M Dube | Common Stock | A | 113,800 | $0.00 | 532,973 | D | A |
| 31 Jan, 2026 | Peter Heerma | Common Stock | A | 26,120 | $0.00 | 139,133 | D | A |
| 31 Jan, 2026 | Sandra Calvin | Common Stock | A | 15,180 | $0.00 | 53,413 | D | A |
| 31 Jan, 2026 | Jula Inrig | Common Stock | A | 28,130 | $0.00 | 114,441 | D | A |